MedTrace Logo

Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)

NCT03307720 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-12-11

No results posted yet for this study

Summary

Agonist triggering in controlled ovarian stimulation protocols is being used during last years (among high responder patients to avoid OHSS).

Indeed, agonist triggering is more physiologic than HCG triggering. Investigators propose to compare the effectiveness of both types of trigger among three different subsets of patients:

1. Poor responders.
2. Normo-responders
3. High responders Comparing both the number and the quality of achieved oocytes.

Conditions

  • Ovulation Induction
  • In Vitro Fertilization (IVF)
  • Infertility, Female
  • Oocytes

Interventions

DRUG

Gonadotropin Releasing Hormone Agonists (GNRH-A)

Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.

DRUG

Human chorionic gonadotropin

Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.

Sponsors & Collaborators

  • Ginegorama S.L.

    lead OTHER

Principal Investigators

  • Gorka Barrenetxea, PhD · Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea

  • Jon Iker Arambarri, MD · Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2018-02-28
Completion
2018-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03307720 on ClinicalTrials.gov